Skip to content
Research Article Open access CC BY 3.0

In Silico Optimized Mechlorethamine Based Drug Structures Targeting Brain and Spinal Cord Tumors

Ronald Bartzatt

Journal of Pharmaceutical Research International · pp. 1058–1069 · Published 28 Aug 2013

10.9734/BJPR/2013/5761

Abstract

Aims: Brain and spinal cord tumors are the third most common type of childhood cancer following leukemia and lymphoma. Mechlorethamine (or mustine) is a nitrogen mustard antineoplastic drug. Eleven variants of mechlorethamine are presented that possess molecular properties enabling substantial access to tumors of the central nervous system. Study Design: An extensive in silico search within a data library of molecular structures identifieddrug scaffolds suitable for targeting brain tumors. Place and Duration of Study:University of Nebraska, Durham Science Center, Department of Chemistry, Omaha, Nebraska 68182 USA, between July 2012 to December 2012. Methodology: Following extensive in silico search and identification of potential drug structures, a conclusive set of brain penetrating structures were compiled. Extensive characterization of structure properties was accomplished followed by multivariate numerical analysis utilizing pattern recognition and statistical analysis. Results: All twelve compounds (including mechlorethamine) exhibited zero violations of Rule of 5, indicating favorable bioavailability. The range in Log P, formula weight, and polar surface area for these compounds are: 1.554 to 3.52, 156.06 to 324.12, and 3.238 A2to 22.24A2,respectively. High resolution hierarchical cluster analysis determined that agent 2 and 6 are most similar to the parent compound mechlorethamine. The average Log P, formula weight, polar surface area, and molecular volume are 2.446, 235.433, 8.58 A2, and 213.8 A3, respectively. Conclusion: These eleven drug designs possess attributes that effectuate high permeation into the central nervous system.

Brain tumors astrocytomas glioma mechlorethamine mustine

References (27)

  1. 1 Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1 [DOI]
  2. 2 Non‐parametric multivariate analyses of changes in community structure [DOI]
  3. 3 Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties [DOI]
  4. 4 Brain metastases: epidemiology and pathophysiology [DOI]
  5. 5 Polar Molecular Surface as a Dominating Determinant for Oral Absorption and Brain Penetration of Drugs [DOI]
  6. 6 Polar Molecular Surface Properties Predict the Intestinal Absorption of Drugs in Humans [DOI]
  7. 7 Estimation of Blood-Brain Barrier Crossing of Drugs Using Molecular Size and Shape, and H-Bonding Descriptors [DOI]
  8. 8 Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood–brain barrier penetration [DOI]
  9. 9 Management of brain metastases [DOI]
  10. 10 Outcome of Children With Metastatic Medulloblastoma Treated With Carboplatin During Craniospinal Radiotherapy: A Children's Oncology Group Phase I/II Study [DOI]
  11. 11 Changing Patterns of Bone and Brain Metastases in Patients with Colorectal Cancer [DOI]
  12. 12 Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. [DOI]
  13. 13 Epidemiology of Primary Brain and Central Nervous System Tumors in Korea [DOI]
  14. 14 Hydrogen-Bonding Capacity and Brain Penetration [DOI]
  15. 15 The treatment of brain metastases in melanoma patients [DOI]
  16. 16 Brain Metastases from Colorectal Cancer: Risk Factors, Incidence, and the Possible Role of Chemokines [DOI]
  17. 17 Breast cancer brain metastases [DOI]
  18. 18 The treatment of brain metastases from malignant melanoma [DOI]
  19. 19 Diagnosis and management of mycosis fungoides.
  20. 20 Clinical manifestation of central nervous system tumor [DOI]
  21. 21 CNS Complications of Breast Cancer [DOI]
  22. 22 MOPP regimen as primary chemotherapy for brain tumors in infants [DOI]
  23. 23 MOPP chemotherapy without irradiation as primary postsurgical therapy for brain tumors in infants and young children [DOI]
  24. 24 Two Separate Episodes of Intramedullary Spinal Cord Metastasis in a Single Patient with Breast Cancer [DOI]
  25. 25 Mechlorethamine, vincristine, and procarbazine chemotherapy for recurrent high-grade glioma in adults: a phase II study. [DOI]
  26. 26 Applying pattern recognition methods to analyze the molecular properties of a homologous series of nitrogen mustard agents [DOI]
  27. 27 Whole brain radiotherapy for the treatment of multiple brain metastases [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

22

Page views

0

PDF downloads

3

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.